Lung cancer diagnostic and screening market comprises various medical instruments, devices and consumables such as biomarkers, imaging tests, endobronchial ultrasound (EBUS) needles, biopsy forceps among others that are used in lung cancer diagnosis and screening to detect early stage lung cancer in asymptomatic individuals. The increasing cases of lung cancer globally is leading to high demand for effective lung cancer diagnostic tests and screening procedures.

The global Lung Cancer Diagnostic and Screening Market is estimated to be valued at US$ 2585.07 Mn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
Rising lung cancer incidence rates across the world present a major market opportunity for lung cancer diagnostic and screening market players. According to WHO, lung cancer is the leading cause of cancer deaths globally. In 2020, there were over 2.2 million new lung cancer cases and 1.8 million lung cancer deaths worldwide. The number of lung cancer cases and deaths is anticipated to surge in the coming years driven by increasing risk factors like smoking, air pollution and aging population. This increases the need for efficient lung cancer screening and diagnostic methods for early detection. Market players catering innovative lung cancer diagnostic solutions and screening programs can expect lucrative growth by tapping into this significant unmet medical need.

Porter's Analysis

Threat of new entrants: Global Lung Cancer Diagnostic And Screening Market Size requires high capital and R&D investments for developing specialized tests and equipment. Stringent regulatory approvals also act as a barrier for new companies.

Bargaining power of buyers: The bargaining power of buyers is moderate as there are many diagnostic service providers and buyers can choose between different testing options.

Bargaining power of suppliers: The key suppliers in this market are diagnostic kit manufacturers and biopharmaceutical companies. Their bargaining power remains moderate due to the availability of substitute products.

Threat of new substitutes: New non-invasive screening and diagnostic techniques pose a threat to existing testing methods. Advancements in AI and big data analytics also enable alternative screening approaches.

Competitive rivalry: The market is dominated by a few leading players. Intense competition exists in areas of pricing, product differentiation, and service quality.

SWOT Analysis

Strengths: Growing demand for accurate screening and diagnosis, availability of reimbursements, technological advancements.

Weaknesses: High cost of treatment, lack of awareness in developing nations, potential side effects of screening tests.

Opportunities: Emerging economies with large patient pools, untapped rural markets, scope for including screening in general health checkups.

Threats: Stringent regulations, social stigma related to lung cancer, competition from alternative treatment options.

Key Takeaways

The global lung cancer diagnostic and screening market is expected to witness high growth over the forecast period due to rising incidence rates worldwide. The global Lung Cancer Diagnostic and Screening Market is estimated to be valued at US$ 2585.07 Mn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024 to 2031.

CT screening is gaining prominence in countries like the US and Japan. Regional growth is projected to be fastest in Asia Pacific owing to increasing healthcare investments, growing per capita incomes, and expanding patient access to diagnostic facilities in high potential markets like India and China. Additionally counties like India and China have huge patient pool and fastest growing economies which will further drive the market in this region.

Key players operating in the lung cancer diagnostic and screening market are ExxonMobil, Chevron Phillips Chemical Company, SABIC, China National Petroleum Corporation (CNPC), and BASF. These companies have strong product pipelines and are focusing on new product launches, collaborations, and clinical trials to strengthen their market presence. Digital diagnostics is also emerging as an important area for key players to explore new opportunities.

Get more insights on this topic- https://www.trendingwebwire.com/lung-cancer-diagnostic-and-screening-market-forecast-insights/